peptide hormone comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-05-16. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Based on the C-terminal region of human growth hormone. |
| Amino acid length | 16 residues | Often described as hGH fragment 176-191. |
| Appearance | Lyophilized powder | Typically white to off-white; exact appearance depends on grade. |
| Solubility | Soluble in water | Aqueous solubility depends on pH, ionic strength, and preparation. |
| Typical storage | -20 °C or lower | Lyophilized peptide is usually kept cold and dry; solutions may require freezing. |
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Evaporation and sublimation into a vacuum is called outgassing. All materials, solid or liquid, have a small vapour pressure, and their outgassing becomes important when the vacuum pressure falls below this vapour pressure. Outgassing has the same effect as a leak and will limit the achievable vacuum. Outgassing products may condense on nearby colder surfaces, which can be troublesome if they obscure optical instruments or react with other materials. This is of great concern to space missions, where an obscured telescope or solar cell can ruin an expensive mission. The most prevalent outgassing product in vacuum systems is water absorbed by chamber materials. It can be reduced by desiccating or baking the chamber, and removing absorbent materials. Outgassed water can condense in the oil of rotary vane pumps and reduce their net speed drastically if gas ballasting is not used. High vacuum systems must be clean and free of organic matter to minimize outgassing. Ultra-high vacuum systems are usually baked, preferably under vacuum, to temporarily raise the vapour pressure of all outgassing materials and boil them off. Once the bulk of the outgassing materials are boiled off and evacuated, the system may be cooled to lower vapour pressures and minimize residual outgassing during actual operation. Some systems are cooled well below room temperature by liquid nitrogen to shut down residual outgassing and simultaneously cryopump the system.
The Neanderthal skull has a flat and broad skullcap, rounded supraorbital torus (the buldge that forms the brow ridges), larger, wide orbits (eye sockets), a broad nose, mid-facial prognathism (the face projects far from the base of the skull), an "en bombe" (bomb-like) skull shape when viewed from the back, a fossa (depression) on the back of the skull below the level of the inion (suprainiac fossa), and an occipital bun (bony projection) at the back of the skull. Like those of other archaic humans, their jaws lack a true chin. The Neanderthal braincase averages 1,640 cm3 (100 cu in) for males and 1,460 cm3 (89 cu in) for females, which is significantly larger than the averages for all 147 homonids studied. The largest Neanderthal brain, Amud 1, was calculated to be 1,736 cm3 (105.9 cu in), one of the largest ever recorded in humans. Neanderthal brain organisation differs in areas related to cognition and language, which may be implicated in the comparative simplicity of Neanderthal behaviour to Cro-Magnons in the archaeological record. Neanderthals had large and wide noses, probably an adaptation to warm greater quantities of cold air to fuel their assumed heightened metabolism and activity levels. A large nose does not necessarily equate to a better sense of smell, and neurologically, because the olfactory bulbs are smaller, Neanderthals may have had a poorer sense of smell and olfactory memory than modern humans.
The mycobiont (fungal partner) of the lichen Lecidea tessellata has been shown to produce confluentic acid when cultured without its algal photobiont partner. Confluentic acid has also been reported from mycobiont cultures of Parmelina carporrhizans. Confluentic acid is produced by almost all species of the genus Immersaria, which is usually accompanied by 2'-O-methylmicrophyllinic acid. The absence of confluentic acid distinguishes Inoderma nipponicum, from others in genus Inoderma, which typically contain this chemical. The only character reliably distinguishing Porpidia contraponenda and the morphologically similar Porpidia cinereoatra is their secondary chemistry: the former contains 2'-O-methylmicrophyllinate and the latter has confluentic acid. A chemosyndrome is a set of biosynthetically related compounds produced by a lichen. The confluentic acid chemosyndrome was identified in several lichens in the family Lecideaceae; it contains confluentic acid as the major metabolite, and minor amounts of 2'-O-methylperlatolic acid, olivetonide monomethyl ether, and 2'-O-methylmicrophyllinic acid. Not just limited to lichen-forming fungi, confluentic acid has also been reported from the Brazilian plant Himatanthus sucuuba, highlighting the compound's broader biological distribution.
Sources: en.wikipedia.org
Arsenic trioxide (ATO) (Latin: Arsenum trioxydatum) is used as a chemotherapeutic agent in the treatment of acute promyelocytic leukemia (APL). It was approved for medical use in the United States in 2000. Arsenic trioxide is also included on the World Health Organization's List of Essential Medicines. Despite its therapeutic use, arsenic trioxide is highly toxic and has historically caused numerous cases of acute and chronic arsenic poisoning. It is classified as an orphan drug and is marketed under the brand name Trisenox. When dissolved in water, it forms arsenous acid. Arsenic trioxide inhibits the proliferation of cancer cells and promotes their differentiation or apoptosis, although its precise mechanism of action remains incompletely understood. Because of its toxicity, arsenic has been used for centuries as a potent poison. Its anticancer properties were recognized in the 20th century, but early efforts to administer it orally were ineffective. Therapeutic benefits were observed only with intravenous administration, particularly in treating the rare cancer acute promyelocytic leukemia. Initially, arsenic trioxide was used to treat APL only after standard retinoid and chemotherapy regimens had failed. However, it is now commonly used as first-line therapy in combination with tretinoin (ATRA) for patients with non-high-risk APL, rather than solely as salvage therapy following relapse. The treatment is generally well tolerated and associated with relatively few side effects. Ongoing research is investigating additional therapeutic applications for this drug.
Further, the method lacks the capability to distinguish between positive and negative nonsynonymous substitutions. Some amino acids are chemically similar to one another, whereas other substitutions may place an amino acid with wildly different properties to its precursor. In most situations, a smaller chemical change is more likely to allow the protein to continue to function, and a large chemical change is likely to disrupt the chemical structure and cause the protein to malfunction. However, incorporating this into a model is not straightforward as the relationship between a nucleotide substitution and the effects of the modified chemical properties is very difficult to determine. An additional concern is that the effects of time must be incorporated into an analysis, if the lineages being compared are closely related; this is because it can take a number of generations for natural selection to "weed out" deleterious mutations from a population, especially if their effect on fitness is weak. This limits the usefulness of the Ka/Ks ratio for comparing closely related populations.
Over the years, multiple synthesizers have been developed to assist with automated synthesis, including the Chemspeed Accelerator (SLT106, SLT II, ASW2000, SwingSLT, Autoplant A100, and SLT100), the Symyx system, and Freeslate ScPPR. Recently, researchers have investigated the optimization of these methods for controlled/living radical polymerization (CLRP), which faces issues with oxygen intolerance. This research has led to the development of oxygen-tolerant CLRP, including with the use of enzyme degassing of RAFT (Enz-RAFT), atom-transfer radical (ATRP) that possesses tolerance to air, and photoinduced electron/energy transfer–RAFT (PET–RAFT) polymerization. Through the use of liquid-handling robots, Tamasi et al. demonstrated the use of automated synthesis with executing multi-step procedures, enabling the reactions to investigate more elaborate schemes, such as with scale and complexity. Lee Cronin and his team have developed a modular synthesis machine called the chemputer which uses a dedicated programming language for chemical synthesis.
Sources: en.wikipedia.org
== Background == Sudan had multi-member Sovereignty Councils holding the role of head of state of Sudan several times during the twentieth century. Following more than half a year of sustained civil disobedience and a shift of the presidency from Omar al-Bashir to the Transitional Military Council (TMC) in April 2019 by a coup d'état, the TMC and the Forces of Freedom and Change alliance (FFC) made a July 2019 Political Agreement and completed it by the August 2019 Draft Constitutional Declaration. Articles 9.(a) and 10.(a) of the August 2019 Draft Constitutional Declaration both transfer the role of head of state to the Sovereignty Council.
However, these authors also found that MOR244-3 lacks the specific metal ion binding site suggested by Suslick, instead showing a different motif in the EC2 domain. Malfunction of the metalloproteins in the olfactory system is hypothesized to have a connection with amyloidal based neurodegenerative diseases.
This term acquired a pejorative connotation in 18th-century Russia, and it currently means "petty bourgeois" or "narrow-minded philistine". The entire city of the late 17th century is contained within contemporary Moscow's Central Administrative Okrug. Numerous disasters befell the city during this period. Plague epidemics ravaged Moscow in 1570–1571, 1592, and 1654–1656. The plague killed more than 80% of the population in 1654–1655. Fires burned down much of the wooden city in 1626 and 1648. In 1712, Peter the Great moved his government to the newly built city of Saint Petersburg on the coast of the Baltic Sea.
Sources: en.wikipedia.org
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.
No. It represents only a short portion of the hGH sequence and lacks the full hormone's structure. As a result, its biological activity and regulatory status differ from those of prescription hGH.
The exact peptide is not typically described as a circulating hormone; it is a synthetic construct based on a natural sequence. Fragments of hGH can exist in laboratory or metabolic contexts, but AOD-9604 itself is manufactured for research.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.